Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension
Open Access
- 1 February 2001
- journal article
- clinical trial
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 15 (2) , 135-141
- https://doi.org/10.1038/sj.jhh.1001137
Abstract
Background: The effect of controlled-onset, extended-release (COER) verapamil on haemodynamic parameters in obese and non-obese patients is evaluated in this analysis. Methods: Data were pooled from three clinical trials evaluating efficacy and tolerability of COER-verapamil. Hypertensive men and women (stage I to III) were randomised to COER-verapamil (180–540 mg at bedtime) or placebo for 4–8 weeks and stratified according to body mass index (BMI-obese >28 kg/m2). Efficacy was assessed as change from baseline in blood pressure (BP), heart rate, and rate-pressure product during four time periods throughout the dosing interval. Safety and tolerability were assessed by monitoring all adverse events and changes in metabolic laboratory parameters. Results: Reductions in all haemodynamic parameters were significantly greater following COER-verapamil compared with placebo for all time periods. The haemodynamic effects of COER-verapamil in obese (n= 166, BMI = 32.8 kg/m2) and non-obese patients (n = 115, BMI = 25.0 kg/m2) were similar. COER-verapamil was well tolerated in both subgroups, but the incidence of constipation was significantly less in obese patients (P < 0.001). Conclusions: COER-verapamil is effective in reducing BP, heart rate, and rate-pressure product independently of BMI.Keywords
This publication has 0 references indexed in Scilit: